Hyperoxaluria - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Hyperoxaluria - Pipeline Review, H2 2016’, provides an overview of the Hyperoxaluria pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hyperoxaluria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperoxaluria and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Hyperoxaluria

The report reviews pipeline therapeutics for Hyperoxaluria by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Hyperoxaluria therapeutics and enlists all their major and minor projects

The report assesses Hyperoxaluria therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Hyperoxaluria

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hyperoxaluria

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hyperoxaluria pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allena Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Dicerna Pharmaceuticals Inc

OxThera AB

Allena Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Dicerna Pharmaceuticals Inc

OxThera AB

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Hyperoxaluria Overview ...

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Hyperoxaluria Overview 6

Therapeutics Development 7

Pipeline Products for Hyperoxaluria - Overview 7

Hyperoxaluria - Therapeutics under Development by Companies 8

Hyperoxaluria - Pipeline Products Glance 9

Clinical Stage Products 9

Early Stage Products 10

Hyperoxaluria - Products under Development by Companies 11

Hyperoxaluria - Companies Involved in Therapeutics Development 12

Allena Pharmaceuticals Inc 12

Alnylam Pharmaceuticals Inc 13

Dicerna Pharmaceuticals Inc 14

OxThera AB 15

Hyperoxaluria - Therapeutics Assessment 16

Assessment by Monotherapy Products 16

Assessment by Target 17

Assessment by Mechanism of Action 18

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Drug Profiles 23

ALLN-177 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

ALLN-230 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

ALN-GO1 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

DCR-PHXC - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Oxabact - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Hyperoxaluria - Dormant Projects 31

Hyperoxaluria - Discontinued Products 32

Hyperoxaluria - Product Development Milestones 33

Featured News & Press Releases 33

Oct 04, 2016: Allena Pharmaceuticals and Health Advances Present Analysis of Recurrent Kidney Stone Disease at the Academy of Managed Care Pharmacy Nexus Conference 33

Sep 07, 2016: Allena Pharmaceuticals Strengthens Leadership Team, Names Edward Wholihan as Chief Financial Officer and Robert Alexander, PhD, to Board of Directors 33

May 05, 2016: FDA Grants Orphan Drug Designation to Allena’s Investigational Therapy for the Treatment of Pediatric Hyperoxaluria 34

Feb 10, 2016: Allena Pharmaceuticals Initiates Patient Treatment in Third Phase 2 Trial of ALLN-177 for Secondary Hyperoxaluria 35

Nov 12, 2015: Allena Pharmaceuticals Announces Presentation of Successful Phase 2 Data from ALLN-177 Program at American Society of Nephrology Kidney Week 36

Nov 04, 2015: Allena Pharmaceuticals to Present Phase 2 Data on ALLN-177 Program at ASN Kidney Week 2015 37

Aug 04, 2015: Allena Pharmaceuticals Initiates Phase 2b Trial of ALLN-177 for Secondary Hyperoxaluria 37

Mar 18, 2015: Allena Pharmaceuticals Announces Positive Phase 2a Data of ALLN-177 for the Treatment of Hyperoxaluria 38

Nov 17, 2014: Allena Pharmaceuticals Presents Phase 1 Data On ALLN-177 At American Society Of Nephrology Kidney Week 2014 39

Nov 10, 2014: Allena Pharmaceuticals To Present Data on Lead Program ALLN-177 at ASN Kidney Week 2014 40

May 15, 2014: OxThera Strengthens Patent Portfolio for Treatment of Hyperoxaluria 40

Apr 29, 2014: Allena Pharmaceuticals Announces Positive Phase 1 Data of ALLN-177 for the Treatment of Kidney Stones 40

Jan 08, 2014: OxThera Initiates Clinical Trial in Primary Hyperoxaluria 41

Jun 04, 2013: OxThera Strengthens Patent Portfolio For Orphan Disease 42

Jun 07, 2012: OxThera Resumes Clinical Development Of Oxabact For Treatment Of Hyperoxaluria 42

Appendix 43

Methodology 43

Coverage 43

Secondary Research 43

Primary Research 43

Expert Panel Validation 43

Contact Us 43

Disclaimer 44

List of Tables

List of Tables

Number of Products under Development for Hyperoxaluria, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis ...

List of Tables

Number of Products under Development for Hyperoxaluria, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Development, H2 2016 10

Products under Development by Companies, H2 2016 11

Hyperoxaluria - Pipeline by Allena Pharmaceuticals Inc, H2 2016 12

Hyperoxaluria - Pipeline by Alnylam Pharmaceuticals Inc, H2 2016 13

Hyperoxaluria - Pipeline by Dicerna Pharmaceuticals Inc, H2 2016 14

Hyperoxaluria - Pipeline by OxThera AB, H2 2016 15

Assessment by Monotherapy Products, H2 2016 16

Number of Products by Stage and Target, H2 2016 17

Number of Products by Stage and Mechanism of Action, H2 2016 18

Number of Products by Stage and Route of Administration, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 22

Hyperoxaluria - Dormant Projects, H2 2016 31

Hyperoxaluria - Discontinued Products, H2 2016 32

List of Figures

List of Figures

Number of Products under Development for Hyperoxaluria, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis ...

List of Figures

Number of Products under Development for Hyperoxaluria, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 10

Assessment by Monotherapy Products, H2 2016 16

Number of Products by Routes of Administration, H2 2016 19

Number of Products by Stage and Routes of Administration, H2 2016 19

Number of Products by Molecule Types, H2 2016 21

Number of Products by Stage and Molecule Types, H2 2016 21

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports